Best Retina Today Podcasts (2025)

1
Treating Geographic Atrophy (GA) In Your Practice 19:18

7d ago19:18

19:18

Sponsored by Apellis Pharmaceuticals. Scott Walter, MD, and Esther Kim, MD, join John W. Kitchens, MD, to discuss how they treat GA in their practices. Listen to gain expert insights as Drs. Kim, Walter, and Kitchens each share their experiences with this treatment. They also share best practices for dosing based on trial data.…

1
Diagnosing Geographic Atrophy (GA) and Identifying Eligible Patients For Therapy 22:07

7d ago22:07

22:07

Sponsored by Apellis Pharmaceuticals. John W. Kitchens, MD, invites Scott Walter, MD, and Esther Kim, MD, to discuss best practices for identifying appropriate patients with GA for treatment. Gain perspectives on patient selection, patient education, and safety considerations.By Retina Today

1
ASRS Leaders & Legends Interview: Lee M. Jampol, MD 29:04

1M ago29:04

29:04

The History of Retina is pleased to welcome revered educator, surgeon, and clinician Dr. Lee Jampol to Leaders & Legends. Dr. Jampol’s remarkable career has largely centered around research trials, studying retinal diseases like diabetic retinopathy and central serous retinopathy. He has been a key player in some of the field's most pivotal trials,…

1
Using OCT Angiography to Distinguish RVO and RAO 17:36

2M ago17:36

17:36

How can OCT angiography help retina specialists distinguish between retinal vein occlusion (RVO) and retinal artery occlusion (RAO) in patients who present without acute findings? Using real-world cases as a backdrop, Yasha Modi, MD, and Kat Talcott, MD, discuss Dr. Modi’s approach to distinguishing RVO and RAO via OCT angiography and review which …

1
OCT Angiography in a Real-world CSR Case 17:59

2M ago17:59

17:59

What role can OCT angiography play in tracking the development of central serous retinopathy (CSR)? Yasha Modi, MD, and Kat Talcott, MD, review the use of OCT angiography in a real-world CSR case, discuss the value of selecting OCT angiography over fluorescein angiography for patients with neovascularization, and parse which populations are not a g…

1
Switching from Aflibercept to Faricimab in Wet AMD Patients 22:00

3M ago22:00

22:00

Does switching wet AMD patients from aflibercept (Eylea, Regeneron) to faricimab (Vabysmo, Genentech) improve disease outcomes? Join Ben Young, MD, MS, and his guests Lediana Goduni, MD, and Joshua Uhr, MD, as they explore this a recent peer review paper on this question. What are the potential benefits of such a switch? How should providers use fi…

1
GA Options in Clinical Therapy: Which Patients Are a Fit for GA Treatment? 16:50

3M ago16:50

16:50

What are the benefits and limitations to FDA-approved therapies for geographic atrophy? John Kitchens, MD, is joined by Saradha Chexal, MD, and Geeta Lalwani, MD, as they explore which patients are best suited for treatment, how best to succinctly set expectations for outcomes, and whether patients on GA therapy may also be well-suited AREDS vitami…

1
AAO '24: Real-world PDR Treatment vs. Protocol S Guidelines, and Retinal Imaging for Alzheimer's 31:38

3M ago31:38

31:38

How many real-world patients with proliferative DR were concordant with the treatment directions in Protocol S? Adrienne Scott, MD, explains how a database review of real-world patients with proliferative DR revealed how few patients are concordant with the strict dosing schedule of Protocol S, and shares which baseline factors were linked to lack …

1
New Retina Radio Journal Club w/ VBS: Does Metformin Reduce AMD Risk? 15:01

4M ago15:01

15:01

Does metformin use reduce the risk of developing AMD in non-diabetic patients? Moderator Rebecca Soares, MD, and panelists Matt Starr, MD, and Nikisha Kothari, MD, review a decade-long case control-control study assessing risk of AMD in non-diabetic patients who have been taking metformin for any reason. They ask whether the study's blindspots unde…

1
AAO '24 Late-Breakers: Preventing Fas Activation Prior to RRD Repair, and Phase 2/3 Data on an Oral Therapy for GA 20:02

4M ago20:02

20:02

We’ve got to keep our eye on the pipeline. What do the latest data tell us about two drug candidates? Durga Borkar, MD, MMCi, reviews data from a phase 2 study assessing the safety and efficacy ONL1204 (ONL Therapeutics) delivered prior to RRD surgery. Did injecting ONL1204, which prevents Fas activation, lead to any postsurgical differences? Alex …

1
AAO '24 Late-Breakers: ELEVATUM Study and Home OCT in Wet AMD 25:27

4M ago25:27

25:27

The ELEVATUM study exclusively enrolled historically underrepresented patients in a study assessing faricimab (Vabysmo, Genentech/Roche) for DME. Were there any surprises in the data? Jeremiah Brown, MD, MS, sits down with New Retina Radio to review the philosophy behind the ELEVATUM study, discuss the study’s findings, and preview the next phases …

1
AAO '24: COVID and Retinal Disease, Plus the Latest on Step Therapy and Declining Reimbursement 31:12

5M ago31:12

31:12

Are retina doctors seeing more retinal pathology following infection or vaccination? Or is there nothing to see here? Rahul Khurana, MD, joins us to discuss the findings of various health care database analyses seeking to clarify whether COVID infection or vaccination were linked to retinal manifestations. Was there a clear—or even an opaque—connec…

1
GA Options in Clinical Therapy: Why Aren't Doctors Embracing Complement Inhibition? 22:50

5M ago22:50

22:50

We finally have two FDA-approved treatments for geographic atrophy (GA)—and yet, many retina specialists have been reluctant to embrace them. Join moderator John Kitchens, MD, as he explores this question with Miguel Busquets, MD, and Esther Kim, MD. Further in the episode, they gameplan patient conversations centered around choosing a treatment, a…

1
How to Give Your Staff Superpowers with Patient Self-Service 18:12

5M ago18:12

18:12

A recent survey found staffing challenges, including hiring and turnover, to be the top challenge for specialty healthcare practices. If alleviating staffing challenges at your practice is a priority, tune in to see how you can break the cycle. Cory Kirspel, Chief Technology Officer at Clearwave, joins us to share what Ophthalmology practices are d…

1
New Retina Radio Journal Club with VBS: Pre-treatment with Chlorhexidine vs. Povidone-Iodine in Endophthalmitis Prevention 16:59

5M ago16:59

16:59

In this episode of the New Retina Radio Journal Club with VBS, Maura Di Nicola, MD; Sruthi Arepalli, MD, and Barton Blackorby, MD, discuss a recent study comparing endophthalmitis rates following anti-VEGF injections with pre-treatment using either 5% Povidone Iodine or 0.05% Chlorhexidine. They highlight how prefilled syringes can reduce the risk …

1
Real-World Studies Reported in Lisbon: Untreated GA Progression and High-Dose Aflibercept in Wet AMD, DME, and DR 28:42

5M ago28:42

28:42

Tens of thousands of real-world geographic atrophy patients were analyzed in a retrospective database study. How did GA progress—and how do these data inform our understanding of GA? Ted Leng, MD, stopped by the show to share the findings from his research on the natural history of GA, which he recently delivered on the podium in Lisbon. And Michae…

1
ASRS Milestones in Retina: History of Anti-VEGF 49:58

6M ago49:58

49:58

Join us for an extraordinary Milestones in Retina expert panel discussion detailing the discovery and evolution of a treatment that truly revolutionized the field of retina and the lives of patients around the world – virtually overnight. That therapy is, of course, anti-VEGF. It goes without saying that there is an army of researchers, clinicians,…

1
New Retina Radio Journal Club w/ VBS: Risk of Death, Stroke, and MI After RAO 16:15

6M ago16:15

16:15

What is the relationship between retinal artery occlusion (RAO) and death, stroke, or myocardial infarction? Moderator Katherine Talcott, MD, is joined by Kyle Kovacs, MD, and Phoebe Mellen, MD, to explore the latest contribution to the literature on this topic. After the break, they discuss how best to manage patients who present to the clinic wit…

1
ASRS ’24: C1q Inhibition and Metformin for AMD 23:43

6M ago23:43

23:43

Could inhibition of C1q effectively halt the progression of GA? Joel Pearlman, MD, PhD, sat down to discuss findings from the phase 2 ARCHER study, which evaluated ANX007 (Annexon) in patients with GA. He tells us what happened when patients were dosed with ANX007 for 1 year—and what occurred when patients stopped receiving treatment. And later, Di…

1
New Retina Radio Journal Club with VBS: Switching to Faricimab in Wet AMD Patients With a History of Anti-VEGF Therapy 17:41

7M ago17:41

17:41

Does switching long-term wet AMD patients to faricimab (Vabysmo, Genentech/Roche) result in meaningful change to disease presentation? Join New Retina Radio Journal Club host Ben Young, MD, MS, and panelists Lediana Goduni, MD, and Josh Uhr, MD, as they break down a recent real-world study published in the literature. After the break, they review w…

1
The Changing Reimbursement Landscape for Retina Practices and How to Keep Up 41:26

7M ago41:26

41:26

Take a listen to the latest episode of ASOA EyeTalks Radio, presented by ASOA Gold Strategic Business Partner, SamaCare. ASOA chats with 30+ year revenue cycle management expert Erin Bishop, RCM COE Manager at EyeCare Partners, and 25+ year medical technology veteran Kip Theno, VP of Provider Partnerships at SamaCare about challenges retina practic…

1
ASRS ’24: PAVILION at 100 Weeks 7:47

7M ago7:47

7:47

The Port Delivery System with Ranibizumab (PDS; Susvimo, Genentech) was shown to be effective for wet AMD treatment. What did the PAVILION study find when it came to treating diabetic retinopathy out to 100 weeks? Margaret Chang, MD, summarized the PAVILION study’s 2-year safety and efficacy findings regarding the PDS in patients with DR but no DME…

1
ASRS ’24: ACP in Patients with Major EZ Attenuation, and GALE Microperimetry Findings 16:16

7M ago16:16

16:16

Is avacincaptad pegol (Izervay, Astellas) effective in patients with major ellipsoid zone attenuation at baseline? Katherine Talcott, MD, stopped by our studio in Stockholm during ASRS with a top-line summary of her lecture at this year’s meeting. And Sunir Garg, MD, joined us for a conversation about the GALE study, which assessed 36 months of con…

1
The AI Revolution in Healthcare with Albert Katz, Co-Founder & CEO at Flagler Health 38:32

7M ago38:32

38:32

This is the Healthcare Executive Insights Podcast presented by The Macallan Group. In this episode, Albert Katz, CEO & Co-Founder of Flagler Health, explores how their AI solutions are transforming musculoskeletal clinics by enhancing patient care and operational efficiency. Flagler Health's innovative AI tools streamline patient triaging and sched…

1
New Retina Radio Journal Club w/ VBS: Risk Factors for Switching from Bevacizumab to Aflibercept in Protocol AC 19:37

8M ago19:37

19:37

Patients with DME in DRCR Retina Network Protocol AC were switched from bevacizumab to aflibercept if they met specific switch criteria. Where there any baseline factors that predicted a switch? Moderator Rebecca Soares, MD, sits down with panelists Matt Starr, MD, and Nikisha Kothari, MD, to review this study, ask whether the findings are clinical…

1
ASRS Leaders and Legends Interview: Mark S. Blumenkranz, MD 32:20

8M ago32:20

32:20

The History of Retina is pleased to share this Leaders & Legends interview featuring the extraordinary life and career of Mark Blumenkranz, MD. Dr. Blumenkranz is the HU Smead Professor Emeritus and co-director of the Ophthalmic Innovation Program at the Byers Eye Institute at Stanford University School of Medicine. In addition, he serves as manage…

1
ASRS Leaders and Legends Interview: Eugene de Juan, Jr., MD, FASRS 29:41

8M ago29:41

29:41

Unlike most kids, Eugene de Juan, Jr., preferred his toys broken. Fascinated by his ophthalmologist father’s many gadgets and his grandfather’s workshop, Gene discovered his passion for fixing things at an early age. He went on to complete his ophthalmology and vitreoretinal training at world-class institutions including the Johns Hopkins Universit…

1
ASRS Leaders and Legends Interview: Emily Y. Chew, MD 27:54

8M ago27:54

27:54

Emily Y. Chew, MD, is director of the Division of Epidemiology and Clinical Applications and deputy clinical director of the National Eye Institute (NEI). She is also a senior investigator and Chief of the NEI’s Clinical Trials Branch. In this Leaders & Legends interview Dr. Chew shares fascinating experiences and perspectives from her extraordinar…

1
From Trials to the Clinic: Using a Therapy With a Novel MOA to Treat Patients With DME 29:41

8M ago29:41

29:41

One of the challenges associated with current anti-VEGF therapies for the management of DME is the need for frequent injections and the potential impact on adherence and vision outcomes. Join Dr. John Kitchens and Dr. Maria Berrocal as they share their experiences treating their DME patients using a therapy with a novel mechanism of action, and how…

1
New Retina Radio Journal Club w/ VBS: RVOs During the COVID Pandemic 15:15

9M ago15:15

15:15

What did a review of the AAO IRIS Registry reveal about the rates of retinal vein occlusion (RVO) during the COVID-19 pandemic? Moderator Katherine Talcott, MD, sits down with Phoebe Mellen, MD, and Kyle Kovacs, MD, to review the study's conclusion that RVO rates did not increase during the pandemic, discuss challenges about talking to patients see…

1
A Treatment With a Novel MOA for Patients With nAMD and DME: Perspectives From the Real World 34:24

9M ago34:24

34:24

Recent studies have proven the therapeutic viability of a different approach in treating retinal vascular diseases. Join Dr. John Kitchens, Dr. Margaret Chang, and Dr. David Chin Yee as they discuss their clinical experiences using a therapy with a novel mechanism of action in patients with nAMD and DME. And, learn how they approach managing patien…

1
AMD and DME Applications in the Retina Practice: Real-world Data 21:08

9M ago21:08

21:08

In the second episode of this 2-part series, moderator Paul Hahn, MD, PhD, and panelists Durga Borkar, MD, MMCi, and Ted Leng, MD, turn to the findings of FARETINA-AMD and FARETINA-DME, which rely on real-world outcomes as documented in the AAO IRIS Registry. What can retina specialists learn from these studies, and how might these studies' finding…

1
The MSO Model You Have Never Heard Of with Will Vanderveer of Redefine Healthcare 19:29

9M ago19:29

19:29

This is the Healthcare Executive Insights Podcast presented by The Macallan Group. In this episode, we speak with Will Vanderveer, CEO at Redefine Healthcare, and explore how Redefine Healthcare is revolutionizing the landscape for independent physicians. Unlike traditional management service organizations (MSOs), Redefine Healthcare operates witho…

1
ARVO 2024 Coverage: UWF Leakage in Protocol AA, Machine Learning, and GA's Link to Anxiety/Depression 22:55

9M ago22:55

22:55

Protocol AA might be complete—but analysis of its data is far from over. What did that study’s data tell us about the relationship between leakage and DR severity? Justis Ehlers, MD, breaks down what he and his team uncovered when examining ultra-widefield images from Protocol AA, and helps us understand how machine learning might be used in future…

1
New Retina Radio Journal Club with VBS: New Retina Radio Journal Club with VBS: Is Buckling Effective for RRD in Patients at Risk for PVR? 13:57

10M ago13:57

13:57

How do outcomes differ for RRD patients at risk of PVR following PPV alone or combined PPV/scleral buckling? Moderator David Xu, MD, hears from panelists Barton Blackorby, MD, and Prethy Rao, MD, MPH, about a recent peer-reviewed paper published in Ophthalmology Retina covering surgical outcomes of patients with RRD who were considered high risk fo…

1
ARVO 2024 Coverage: ≥20-week Dosing in PULSAR and TENAYA/LUCERNE 16:00

10M ago16:00

16:00

Could next-generation anti-VEGF agents such as faricimab (Vabysmo, Genentech/Roche) and high-dose aflibercept (Eylea HD, Regeneron) be dosed as infrequently as every 20 weeks without sacrificing efficacy? And even if there are data that suggest that finding, would anyone actually adopt an interval that long in wet AMD patients? Philip Storey, MD, f…

1
ASRS Leaders and Legends Interview: Drs. Susan B. and Neil M. Bressler 39:46

10M ago39:46

39:46

Leaders & Legends is pleased to share an interview with a true dynamic duo in retina: Drs. Susan and Neil Bressler. Susan and Neil’s personal and professional partnership started in their early days at John Hopkins medical school and, with thoughtful intention, they set out to build their life and careers together. They both pursued ophthalmology r…

1
GA Options in Clinical Therapy, Part 2: Real-world Cases in GA 17:20

10M ago17:20

17:20

David RP Almeida, MD, PhD, MBA; Lisa Faia, MD; and Chris Riemann, MD, return for the second episode in this podcast miniseries, in which they review a trio of real-world GA cases, explore what early responses to treatment look like, and ask how to address GA in the presence of wet AMD.By Retina Today

1
GA Options in Clinical Therapy, Part 1: Patient Selection and Treatment Strategies 23:42

10M ago23:42

23:42

Join David RP Almeida, MD, PhD, MBA; Lisa Faia, MD; and Chris Riemann, MD, as they assess which clinical and non-clinical characteristics drive their decision-making in patients with geographic atrophy (GA). After the break, Dr. Faia shares a real-world case from her clinic in which a patient who was lost to follow-up returns to consider treatment.…

1
AMD and DME Applications in the Retina Practice: RCT Comparison 21:13

10M ago21:13

21:13

What conclusions can be drawn from a cross-trial comparison of randomized clinical trials assessing the safety and efficacy of anti-VEGF agents used in the treatment of AMD and DME? Paul Hahn, MD, PhD, sits down with Durga Borkar, MD, MMCi, and Ted Leng, MD, to review a recent presentation by Dr. Leng on this topic, and to examine the clinical rele…

1
The State of Biosimilars: Integration of Biosimilars into a Retina Practice 22:03

11M ago22:03

22:03

Biosimilars in retina are here. How are practices integrating them into their clinics? And how do they navigate issues around payer policy, protocol changes, and ensuring continuity of care? Moderator John Kitchens, MD, sits down with retina specialist Dave Brown, MD, and Kristin Yockus, the VP of Process Integrations at Retina Consultants of Ameri…

1
New Retina Radio Journal Club with VBS: Comparison of Antiseptics Use for IVT 15:48

11M ago15:48

15:48

How do endophthalmitis rates after intravitreal injection differ after using povidone-iodine compared with chlorhexidine? Moderator Sruthi Arepalli, MD, hears from panelists Vaidehi Dedania, MD, and Rebecca Soares, MD, MPH, about a recent peer-reviewed retrospective cohort study on this topic. After the break, the trio discuss how to manage patient…

1
Improving Patient Care Through SOPs and Innovative Technologies with Kelly Ladd at Piedmont Internal Medicine 43:48

11M ago43:48

43:48

This is the Healthcare Executive Insights Podcast presented by The Macallan Group. In Episode 51, we speak with Kelly Ladd, CEO of Piedmont Internal Medicine. Kelly has extensive experience in healthcare management, particularly in private physician practices. She shares her journey and insights with us, highlighting the importance of adaptability …

1
Developing a Culture to Thrive and Prevent Burnout with Quinn McCullough at Scottsdale Detox Center and The Hope House 50:44

11M ago50:44

50:44

This is the Healthcare Executive Insights Podcast presented by The Macallan Group. In Episode 52, we sit down with Quinn Davidson, who shares the innovative approach of Scottdale Detox Center and The Hope House in tackling substance abuse. Their focus on individualized and comfortable care in a holistic, trauma-informed environment aims to address …

1
How to Know If You Are a P.O.W.E.R.F.U.L. Leader 8:43

11M ago8:43

8:43

Commit to building empowered relationships that achieve mutually rewarding goals. Nurture healthy interdependence with your staff, your family/friends and community to live/work with a shared sense of wholeness, safety, and purpose.

1
Successful Management of Vitreous Opacities 25:38

12M ago25:38

25:38

Performing surgery for symptomatic vitreous opacities (SVO) was once verboten in retina medicine, but the field has seen a sea-change in mindset over the past decade. In this podcast, moderator John Kitchens, MD, is joined by Edwin H. Ryan, MD; Christina Y. Weng, MD, MBA; and Alison Bozung, OD, to explore why surgery for SVO has become more palatab…

1
New Retina Radio Journal Club with VBS: Visual Outcomes Following Surgical RRD Repair Relative to Foveal Status and Time of Surgery 20:17

12M ago20:17

20:17

Do the status of the fovea and/or the timing of surgery affect visual outcomes following RRD repair? Join New Retina Radio Journal Club host Lediana Goduni, MD, as she and panelists Matt Starr, MD, and Joshua Uhr, MD, dissect the findings of a recent paper exploring this question. After the break, the trio discusses tactics for overcoming challenge…

Podcasts Worth a Listen

Retina Today Podcasts

Podcasts Worth a Listen

Quick Reference Guide